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Increased fracture risk is generally associated with the
reduced bone mineral density (BMD) found in osteoporotic
and osteopenic individuals, but the relationship between
bone mass and fracture risk is an imperfect one. The results
of anti-resorptive treatment on BMD and fracture risk pro-
vide the best example of this. The maximal fracture reduc-
tion with treatment occurs in the first year of treatment,
whereas BMD continues to increase for at least several more
years1-4. Black et al. in a meta-analysis of 13 randomized tri-
als which used alendronate, raloxifene, calcitonin, estradiol,
etidronate, risedronate or tiludronate found that the
observed fracture risk reduction from anti-resorptive thera-
pies was at least twice as large as would be expected from the
changes in BMD alone5. Moreover, despite differences in
the extent to which the different compounds increase BMD,
reductions in spine fracture after three years are all similar6
(Table 1). 
The disconnect between BMD and fracture risk is often
attributed to the quality of the bone matrix. “Bone quality”
is used and defined in a variety of ways. In this session, three
aspects of bone matrix quality will be considered: (1) colla-
gen effects (Dr. Bailey); (2) mineral effects (Dr. Boskey); (3)
architectural effects independent of bone mineral, including
those induced by changes in bone turnover rate (Dr.
Weinans). The role that anti-resorptive therapies play in
altering the mineral fraction itself and how these might be
responsible for the greater than expected reduction in frac-
ture incidence will be addressed by Dr. Boivin.
A biomechanical understanding of the potential effects of
variations in collagen, mineral and architecture is a neces-
sary prerequisite to an understanding of how such changes
might affect the amount of energy required to fracture a
bone. Dr. Turner will set the stage for a discussion of varia-
tions in bone matrix and architecture by examining the bio-
mechanical implications of changes in tissue quality.
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Compound Increased BMD Reduction in fracture incidence
Alendronate1, 2 6.2% 50%
Risedronate3 5.4% 41%
Raloxifene7 2.6-2.7% 34-47%
Calcitonin8 1-2% 30-35%
Table 1. Increased vertebral BMD and reduced fracture incidence after
three years’ treatment with four anti-resorptive compounds.
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